ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression

Oncogene. 2006 Aug 31;25(39):5462-6. doi: 10.1038/sj.onc.1209536. Epub 2006 Apr 10.

Abstract

The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for cells participating in such interactions, and only few genes are known to play a critical role in this process. Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer). Moreover, we show that ADAM12 is essential for tumor development and progression in the W10 mouse model for prostate cancer. These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / genetics*
  • ADAM12 Protein
  • Animals
  • Antineoplastic Agents / pharmacology
  • Cell Division / drug effects
  • Disease Progression
  • Female
  • Gene Expression Regulation, Neoplastic
  • Intestinal Neoplasms / genetics
  • Male
  • Mammary Neoplasms, Animal / genetics
  • Mice
  • Prostatic Neoplasms / pathology*
  • Stromal Cells / pathology*

Substances

  • Antineoplastic Agents
  • ADAM Proteins
  • ADAM12 Protein
  • Adam12 protein, mouse